Lodha Vs Lodha: How did Lodha family feud unfold – A timeline

The family feud between real estate moguls Abhishek Lodha and Abhinandan Lodha continued to escalate over the ‘Lodha’ trademark dispute, with the most recent development being Abhishek Lodha’s Macrotech Developers filing a Rs 5,000 crore lawsuit against the younger brother’s firm, the House of Abhinandan Lodha (HoABL). The brand infringement lawsuit, filed on January 20 in the Bombay High Court, seeks to restrain HoABL from using the word ‘Lodha’ in any form, claiming exclusive trademark rights to the name. The hearing is now scheduled for January 27.

The issue has been in the making since years now fuelled by longstanding disputes over the use of the ‘Lodha’ brand. Abhinandan Lodha had left the family business in 2017 to start the plotted development firm The House of Abhinandan Lodha (HoABL) under Lodha Ventures, which also include startup acceleration and other verticals.

The Lodha brothers are sons of BJP leader and Maharashtra cabinet minister Mangal Prabhat Lodha.

Also ReadUltraTech Cement Q3 Results: Profit drops by 16.98% to Rs 1,473.51 crore, beats estimates

Here is a look at how the events unfolded over the years and what’s the take of Lodha duo these:

Lodha Group was founded in early 1980s and it was in the business of offering residential and commercial properties under the brand name ‘Lodha’. The company saw a significant increase in debt between 2008 and 2024, which caused a lot of stress in the family. In 2011, the income tax department conducted raids on the company which led to damage to the company’s reputation. In 2014-15, governance issues were identified in the finance department which, at the time, was led by Abhinandan Lodha, according to the details shared by Macrotech. 

Between 2015-2017, document shared by Macrotech stated, while initially it was agreed that each family member would take some assets and some debt, at later stage, Abhinandan Lodha insisted that “he does not want to handle so many customers, debt and construction and hence, wants only money”. This led to Abhishek Lodha and his parents left with Rs 20,000 crore of debt and Abhinandan Lodha separated to start a new business with payout of approximately Rs 10,000 crore. “Between 2015 and 2020, Abhishek Lodha and the family went through a ‘near death experience’ due to this baggage of huge debt,” the document maintained. 

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth